SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
BioMed Momentum Index: Pause that Refreshes or More Pain to Come?
CTIC
|
|
|
-10.87%
in
10 days
Below is a 10-stock BioMed Momentum Index that I have created along with related financial data from Google Finance as of 10/28/09, including the stock price, 52-week change, average daily trading volume, and market cap. I have screened for small and micro-cap stocks with market caps of approximately $500 million (M) or lower with stock price increases of at least 50% in the past year and average trading volume of at least 1M shares per day. <> 1.) Antigenics (NASDAQ: AGEN) ($...
|
Short Cell Therapeutics, Inc (CTIC)
CTIC
|
|
|
+22.00%
in
40 days
(closed on 11/05/09)
Insiders are selling
Revenues are down
EPS are down
CTIC underperform compare with the market last 3m
Make Money - http://www.money-top10.com/
Investments - http://www.stockpicksexpert.com/
Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires,
and commercializes oncology products for cancer treatment. Its development
portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin?s
lymphoma; Brostallicin, which is in first-line Phase II study for the treatment
of sarcoma; and OPAXIO, a chemotherapeuti...
|
CTIC has to move soon
CTIC
|
|
|
-34.62%
in
87 days
This is a stock that sold near $400.00 at one time and now is looking forward to a lot of positive news at $1.50. I continue to sell other stocks to buy CTIC and FTWR.
|
FDA Calendar Updates: Cell Therapeutics (NASDAQ:CTIC)
CTIC
|
|
|
-38.67%
in
92 days
(closed on 10/29/09)
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 285 entries as of 7/29/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the F...
|
Extreme FDA Calendar Trades: 21 Stocks Under $5
CTIC
|
|
|
+2.74%
in
9 days
(closed on 07/29/09)
<> Below are extreme trades among 21 companies with stock prices under $5 from the <font> BioMedReports.com FDA Calendar </font> , which includes 264 entries as of 7/20/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of <font> BioMedReports.com </font> , the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submi...
|
From the Blogosphere
Encouraging Data for Pixantrone
|
Yesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone.
|
Encouraging Data for Pixantrone
|
|
|
Yesterday, Cell Therapeutics (CTIC) released encouraging data from the 18-month follow-up clinical trial of pixantrone.
|
Cell Therapeutics spikes on FDA approval
Filed under: Good news, Options  Cell Therapeutics Inc. (NASDAQ: CTIC) caught a boost this morning after the U.S. Food & Drug Administration (FDA) accepted its new drug application for pixantrone, an experimental drug for the treatment of relapsed, aggressive non-Hodgkin's lymphoma. The FDA's action date for review of pixantrone will be set by Sept. 4.
<>CTIC surged more than 6% out of the gate this morning, tagging a session high of $1.80, but the low-priced shares have since whittled their gains. The equity, which has rallied 1,107.1% year-to-date, is currently trading sideways between support...
|
Cell Therapeutics' Turnaround Remains on Track
The dramatic turnaround from lows of a nickel per share ealier this year at cancer biotech Cell Therapeutics (NASDAQ:CTIC) remains on track as the Company announced its 1Q09 results Thursday, which included a 76% reduction of net loss and expected completion of the pixantrone NDA filing this June. Earlier this week, CTIC announced that pixantrone was made available through a compassionate use program in Europe on a named-patient basis for use in the treatment of aggressive non-Hodgkin's lymphoma ((NHL)) that has either relapsed or is refractory to standard treatment options. <> CTIC achivied i...
|
Cell Therapeutics Reemerging
by Mike Havrilla I profiled Cell Therapeutics (CTIC) two months ago as a cancer biotech that was down, but not out. Since then the stock price has more than quadrupled from $0.08 cents to $0.36 cents during intraday trading. CTIC continues to reduce operating expenses, and sold its remaining stake in a joint venture to market the cancer drug Zevalin to Spectrum Pharma (SPPI) for $16.5M last month (in addition to receiving $15M last December from SPPI for the initial 50% stake).
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on CTIC |
Visit streetinsider.com
Chart Alerts for April 14
- Here is a link to some chart alerts for April 14th
http://www.stockhideout.com/sas-nightly-chart-scans/2809-chart-alerts-april-14-a.html
|
More Resources
|
About Cell Therapeutics Inc
- Answers.com
